AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Business

Bristol Myers Squibb and AbbVie to Cut 360 Jobs Across CA

Both Bristol Myers Squibb and AbbVie filed a WARN notice with the California state government stating they intend to lay off up to 360 people.

September 19, 2022

2 min read

Mark Terry

Bio NC

The Top Biopharma Companies Hiring New Grads Across the U.S.

Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.

August 19, 2022

2 min read

Rosemary Scott

SKYRIZI is the new option for psoriatic arthritis.

Business

Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab

I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.

August 17, 2022

2 min read

Vanessa Doctor, RN

Career Advice

How Removing Bias From Job Descriptions is Key to Your Company’s Success

Job descriptions are the candidate’s first impression of a company. And if that introduction includes exclusionary language, they’re less likely to apply even if they are the perfect fit for the job.

August 9, 2022

5 min read

Kaley Lefevre

Gold colored 2022 sitting over American Dollar bills. Selective focus. Horizontal composition with copy space. Money printing and inflation concept.

Business

Do Q2 Results and Increased M&A Indicate a Recovery for Biotech?

A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.

August 8, 2022

3 min read

Alex Keown

Business

AbbVie and Sosei Lead Slate of Early August R&D Deals

AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

August 2, 2022

4 min read

Mark Terry

Job Trends

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

July 26, 2022

20 min read

Courtesy of picture alliance/Getty Images

Drug Development

Sandoz Takes Aim at AbbVie’s Humira with FDA Acceptance of Biosimilar Application

Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.

July 21, 2022

3 min read

Alex Keown